Clinical trials: Cardiovascular Event
Acute Coronary Syndrome
A Comparison of the TIMI, GRACE and HEART Scores
Various elements of patient history are checked and entered in the admission Case Recor Form (CRF). Three risk scores are calculated out of these elements, combined with physical examination, laboratory values and ECG-findings.
- Trial name
- HEART (NCT01398631)
- Where
- 10 sites in Netherlands
- Volunteers
- 2,440 people
- Sponsor
- R&D Cardiologie
Hip Fractures, Perioperative Myocardial Ischemia
Lumbar Plexus Block Upon the Incidence of Ischemic Cardiovascular Events in Elderly Patients With Hip Fracture
The purpose of this study is evaluate the efficacy of perioperative continuous lumbar plexus block in reducing the risk of cardiac ischemic events of elderly patients undergoing surgery for hip fractures, expressed as a reduction…
- Trial name
- NCT01961895
- Testing
- Continuous lumbar plexus (LP) block analgesia, Intravenous patient-controlled analgesia
- Where
- 2 sites in Chile
- Volunteers
- 31 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Post-immunisation Apnoea and Bradycardia of Prematurity (AOP)
Predictive Value of Heart Rate Variability on Cardiorespiratory Events
The aim of this study are to investigate whether heart rate variability (HRV) parameters derived from nonlinear time series analysis at five different time points have prognostic utility for assessing the risk of postimmunisation…
- Trial name
- NCT04303494
- Testing
- immunisation
- Where
- Switzerland
- Volunteers
- 292 people
- Sponsor
- University Hospital, Basel, Switzerland
Advanced Hormone Sensitive Prostate Cancer
Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year.
- Trial name
- NCT02229253
- Testing
- degarelix
- Where
- Netherlands
- Volunteers
- 112 people
- Sponsor
- Ferring Pharmaceuticals
Myocarditis
Incidence, Patient Characteristics and Outcome of Myocarditis After COVID-19 mRNA Vaccine
This study evaluates the incidence, patient characteristics and outcome of myocarditis after the COVID-19 mRNA vaccination in healthcare professionals.
- Trial name
- MACIS (NCT05438472)
- Testing
- data collection in healthcare professionals with COVID-19 mRNA vaccine booster
- Where
- Switzerland
- Volunteers
- 835 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Major Cardiovascular Events
Impact of Triglyceride-Glucose Index on Cardiovascular Outcomes in Patients Presented With MINOCA
This work was designed to explore the role of the triglyceride-glucose (TyG) index in the prediction of cardiovascular outcomes in Patients Presented with myocardial infarction with nonobstructive coronary arteries.
- Trial name
- NCT06066177
- Testing
- Triglyceride glucose index TyG
- Volunteers
- 100 people
- Sponsor
- Assiut University
Peripheral Arterial Disease(PAD)
Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with PAD：Phase II
This study is a multicenter, prospective, observational research project. It is anticipated to enroll a total of 6,000 patients between February 1, 2025, and January 31, 2028 (with completion of one-year postoperative follow-up…
- Trial name
- NCT06850207
- Volunteers
- 6,000 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Myocardial Infarction
RElevance of Biomarkers for Future Risk of Thromboembolic Events in UnSelected Post-myocardial Infarction Patients
The study is an open, single center, observational study at the Cardiology Dept at Uppsala University Hospital. The number of patients included will be 410.
- Trial name
- REBUS (NCT01102933)
- Where
- Sweden
- Volunteers
- 425 people
- Sponsor
- Uppsala University
Venous Thromboembolism
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
- Trial name
- NCT05966740
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim